what do glp-1 receptor agonists do Understanding and their impact on drug discovery GLP-1 Receptor Agonists as Treatments

Recent developments underscore the relevance of GLP-1R agonists in addressing the complex interplay of cardiovascular-kidney-metabolic (CKM) syndrome, microvascular dysfunction, and metabolic-associated steatohepatitis (MASH)

Additionally, several key clinical trial readouts delivered compelling data across multiple indications, for example (see Figure 1): Semaglutide: STEP-HFpEF (functional benefits in HFpEF), STEP-9 (pain reduction in knee osteoarthritis), STEP-10 (reversion to normoglycaemia in pre-diabetic, obese patients), ESSENCE (resolution of MASH, improvement in fibrosis) Tirzepatide: SUMMIT (risk reduction in HFpEF outcomes

Semaglutide was approved in 2017 as Ozempic for diabetes, and in 2021 as Wegovy for obesity

Graphic Abstract

Our blog series on GLP-1 agonists for weight loss is aimed at unpacking the science behind this new frontier in weight management, presenting a detailed overview of how they work, their efficacy, and their role in a holistic approach to health and wellness.

The agency urges consumers not to purchase these products which are of unknown quality and may be harmful to their health.GLP-1 prescription drugs should not be confused with GLP-1 dietary supplements. These products marketed to boost GLP-1 naturally, promote weight loss, or provide nutritional support for those taking GLP-1 medications contain a variety of dietary supplement ingredients, not actual GLP-1 drugs.Bottom LineGLP-1 drugs are prescription medications, not dietary supplements